Azizoddin, Desiree R.
DeForge, Sara M.
Baltazar, Ashton
Edwards, Robert R.
Allsop, Matthew
Tulsky, James A.
Businelle, Michael S.
Schreiber, Kristin L.
Enzinger, Andrea C.
Funding for this research was provided by:
National Palliative Care Research Center
National Institutes of Health-National Cancer Institute, United States (R21CA263838, R21CA263838, R21CA263838, R21CA263838)
NIH National Cancer Institute (NCI-P30CA225520, NCI-P30CA225520)
Oklahoma Tobacco Settlement Endowment Trust (R23-02, R23-02)
Article History
Received: 29 August 2023
Accepted: 5 January 2024
First Online: 22 January 2024
Declarations
:
: The study protocol was approved by Dana-Farber Cancer Institute (No: 20–453 exempted 12/07/2020; No: 21–719 approved 5/23/2022, TRN: NCT05403801 registered 05/06/2022) and Stephenson Cancer Center (No: 13725 approved 12/13/2021) Institutional Review Boards. Participants provided informed consent to participate and study activities conformed to the 1964 Helsinki Declaration and following amendments.
: MSB is the primary inventor of the Insight™ mHealth Platform, which was used to develop the app described in this manuscript. MSB receives royalties related to the Insight™ Platform, but he did not receive royalties in this case. The remaining authors have no relevant financial or non-financial interests to disclose.